|  TGase Protein Labeling Kits  |  
|  Transglutaminase  |  
|  Reaction stopper  |  
|  Amine-donors  |  
|  Glutamine-donor peptides  |  
|  TGase Labeling Service  |  
| Substance | 
|---|
| Kits 12 | 
| Label | 
| Biotin 2 | 
| Atto-488 1 | 
| PEG1,088 2 | 
| Atto-532 1 | 
| Atto-550 1 | 
| Atto-647N 1 | 
| Atto-700 1 | 
| Dansyl 1 | 
| PEG5,000 2 | 
| Application | 
| Protein labeling 12 | 

| Art. No. | Name | Unit | Price | 
|---|---|---|---|
| L001 |  Substrate Finder Kit  |  1 Kit | 450 € | 
| Art. No. | Name | Unit | Price | 
|---|---|---|---|
| L201 |  Biotin TGase Protein K-Labeling Kit  |  1 Kit | 650 € | 
| L202 |  PEG1,088 TGase Protein K-Labeling Kit  |  1 Kit | 650 € | 
| L203 |  PEG5,000 TGase Protein K-Labeling Kit  |  1 Kit | 650 € | 
Successful ISO9001:2015 recertification 
Besuch des Bundesministers für Wirtschaft und Klimaschutz Dr. Robert Habeck bei der Zedira 
Successful ISO9001:2015 recertification 
Dr. Falk Pharma and Zedira announce successful completion of the phase 2a proof-of-concept study of ZED1227 for the treatment of Celiac Disease 
Dr. Falk Pharma und Zedira verkünden den erfolgreichen Abschluss der Phase 2a-Studie mit ZED1227 zur Behandlung von Zöliakie 
Reversibly acting transglutaminase 2 inhibitors: drug candidates for the treatment of fibrosis 
Transcriptomic analysis of the efficacy of TG2-inhibitor trials and human intestinal organoids modelling Celiac disease pathogenesis 
Transglutaminase antibodies and neurological manifestations of gluten sensitivity 
Design of Oral FXIIIa Blockers as Safer Anticoagulants Mission Impossible? 
Microbial transglutaminase (MTG) enables efficient and site-specific conjugation to native antibodies without the need of antibody engineering 
Tridegin as FXIIIa inhibitor 
Microbial transglutaminase: from discovery to market 
Tissue transglutaminase inhibitors 
Tissue transglutaminase in Alzheimers Disease 
Factor XIIIa: novel target for anticoagulation? 
Microbial transglutaminase for site-specific protein conjugation